Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Gram-negative bacterial outer membrane is a specialized asymmetric bilayer where the inner leaflet is composed of phospholipids and the outer leaflet is predominantly lipopolysaccharide (LPS) (Nature Reviews Microbiology, 2010). Lipid A is the highly conserved, hydrophobic anchor of LPS and serves as the primary target for cationic antimicrobial peptides and lipopeptides like polymyxins (StatPearls, 2023). This target is essential for maintaining the structural integrity and selective permeability of the bacterial cell envelope, protecting the organism from environmental stressors and many antibiotics (Frontiers in Microbiology, 2020). In the context of human disease, Lipid A acts as a potent endotoxin, triggering a robust inflammatory response through the TLR4 signaling pathway, which can lead to sepsis and septic shock (Journal of Endotoxin Research, 2006). Drugs like polymyxins interact with this target by binding to the negatively charged phosphate groups of Lipid A and phospholipids, displacing stabilizing divalent cations and causing lethal membrane disruption (Journal of Antimicrobial Chemotherapy, 2014). Despite their efficacy against multidrug-resistant pathogens, targeting these membrane components is often associated with significant clinical challenges, including nephrotoxicity and the development of resistance through modification of the Lipid A structure (Clinical Microbiology Reviews, 2017).
Binding to negatively charged phosphate groups of lipid A and phospholipids, displacement of divalent cations (Mg2+ and Ca2+), and subsequent disruption of the outer and inner bacterial membranes (StatPearls, 2023; Journal of Antimicrobial Chemotherapy, 2014).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gram-negative bacterial outer membrane lipopolysaccharide lipid A and phospholipids (LPS/Lipid A).